Immunotherapy in the treatment landscape of hormone receptor-positive (HR+) early breast cancer: is new data clinical practice changing?
-
Published:2024-09
Issue:9
Volume:9
Page:103695
-
ISSN:2059-7029
-
Container-title:ESMO Open
-
language:en
-
Short-container-title:ESMO Open
Author:
Zagami P.ORCID,
Cortés J.,
Carey L.A.ORCID,
Curigliano G.ORCID
Reference21 articles.
1. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial;Johnston;Lancet Oncol,2023
2. LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2− primary breast cancer (BC);Loi;Ann Oncol,2023
3. LBA21 KEYNOTE-756: phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer;Cardoso;Ann Oncol,2023
4. Neoadjuvant chemotherapy and immunotherapy in luminal B-like breast cancer: results of the phase II GIADA trial;Dieci;Clin Cancer Res,2022
5. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer;Nanda;JAMA Oncol,2020